Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Leclanche Aktie 11030311 / CH0110303119

05.01.2026 18:00:04

Leclanché Restarts M3 Module Production Line Following Incident

Leclanché SA / Key word(s): Miscellaneous
Leclanché Restarts M3 Module Production Line Following Incident

05.01.2026 / 18:00 CET/CEST


Leclanché Restarts M3 Module Production Line Following Incident

YVERDON-LES-BAINS, Switzerland, 5th of January 2026 – Leclanché SA, one of the world’s leading energy storage companies, announces the restart of its M3 module production line in Yverdon-les-Bains following the incident reported on the 26th of November 2025.

After a couple of weeks of testing and validation, modules have been successfully produced in test mode before the Christmas break. Following this test period, standard production has resumed as
of Monday 5th of January 2026 under adapted operating conditions until the equipment damaged during the incident is fully replaced. The adapted operating conditions are to take in to account offline quality testing while the inline testing station is being repaired.  None of the assembly process steps have been modified or degraded, so we maintain full product compliance and full production
capacity on the key assembly steps.

Production operations will continue during the full replacement period with a gradual ramp-up planned over the coming weeks.  We expect to reach close to full production capacity in this mode, and full production capacity is expected to be restored once the new equipment is installed.

The supply disruption to clients following the incident has been minimal, and with the restart of module production, we will be able to maintain the supply of goods to our customers, including battery pack assembly in Germany.

Pierre Blanc, Group CEO & CTIO of Leclanché said: “I would like to sincerely thank our engineering, EHS, and production teams for their exceptional commitment and responsiveness, as well as our suppliers for their valuable support during the assessment and recovery phase. Their collective efforts have been instrumental in enabling the safe and timely restart of the line.”

Leclanché will continue to provide updates should new material information become available.

 

 

# # #

 

 

About Leclanché

Leclanché is a world leading provider of low-carbon footprint energy storage solutions based on lithium-ion cell technology. Established in 1909 in Yverdon-les-Bains, Switzerland, Leclanché’s history and heritage is rooted in battery and energy storage innovation. The company’s Swiss culture for precision and quality, together with its production facilities in Germany, make Leclanché the partner of choice for companies seeking the very best in battery performance and who are pioneering positive changes in how energy is produced, distributed and consumed around the world. Leclanché is organised into three business units: energy storage solutions, e-Mobility solutions and specialty battery systems. The company currently employs over 350 people with representative offices in eight countries around the world. Leclanché is listed on the Swiss Stock Exchange (SIX: LECN).

SIX Swiss Exchange : ticker symbol LECN | ISIN CH 011 030 311 9

 

Disclaimer

This press release contains certain forward-looking statements relating to Leclanché's business, which can be identified by terminology such as "strategic", "proposes", "to introduce", "will", "planned", "expected", "commitment", "expects", "set", "preparing", "plans", "estimates", "aims", "would", "potential", "awaiting", "estimated", "proposal", or similar expressions, or by expressed or implied discussions regarding the ramp up of Leclanché's production capacity, potential applications for existing products, or regarding potential future revenues from any such products, or potential future sales or earnings of Leclanché or any of its business units. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of Leclanché regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Leclanché's products will achieve any particular revenue levels. Nor can there be any guarantee that Leclanché, or any of the business units, will achieve any particular financial results.

 

Media contacts: 

Switzerland / Europe: 
Thierry Meyer
T: +41 (0) 79 785 35 81
E-Mail: tme@dynamicsgroup.ch

Germany:
Christoph Miller
T: +49 (0) 711 947 670
E-Mail: leclanche@sympra.de

Investor contacts:
Pierre Blanc
T: +41 (0) 24 424 65 00
E-Mail: invest.leclanche@leclanche.com



End of Media Release
View original content: EQS News


Language: English
Company: Leclanché SA
Av. des Sports 42
1400 Yverdon-les-Bains
Switzerland
Phone: +41 (24) 424 65-00
Fax: +41 (24) 424 65-20
E-mail: investors@leclanche.com
Internet: www.leclanche.com
ISIN: CH0110303119, CH0016271550
Valor: A1CUUB, 812950
Listed: SIX Swiss Exchange
EQS News ID: 2254868

 
End of News EQS News Service

2254868  05.01.2026 CET/CEST

Analysen zu Leclanche (Leclanché SA)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Longevity = mehr Rendite? Dr. Anna Erat über Healthspan & Investments – zu Gast im BX Morningcall

Im neuesten BX Morningcall ist Dr. Anna Erat zu Gast – Spezialistin für Innere Medizin, Sportmedizin, Prävention und Longevity. Gemeinsam mit Olivia Hähnel und François Bloch sprechen wir darüber, was Longevity wirklich bedeutet (Healthspan vs. Lifespan), warum es mehr ist als Biohacking und wie man seriöse Angebote von Hype unterscheidet.

Dr. Erat gibt Einblick, wie eine erste Longevity-Konsultation abläuft, welche Rolle Anamnese, Genetik/Epigenetik und Technologie/AI spielen und worauf Patientinnen und Patienten bei der Wahl eines Anbieters achten sollten. Ausserdem: Versicherung & Kostenübernahme in der Schweiz, Erwartungsdruck bei High-Performance-Klienten und ein spannender Case: Wie würde sie mit Lindsey Vonn nach einer Verletzung umgehen?

https://bxplus.ch/bx-musterportfolio/

Longevity = mehr Rendite? Dr. Anna Erat über Healthspan & Investments – zu Gast im BX Morningcall

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 14’510.58 20.00 SAIB4U
Short 14’818.22 13.86 B58SLU
Short 15’377.31 8.89 SJUBNU
SMI-Kurs: 13’977.10 25.02.2026 17:30:17
Long 13’354.21 19.17 S63BSU
Long 13’068.54 13.79 SVRB0U
Long 12’506.52 8.92 S1FBQU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com